Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) has issued an update.
Zylox-Tonbridge Medical Technology Co., Ltd. has announced the convening of its 2025 first extraordinary general meeting to discuss and potentially approve a Share Incentive Scheme. This scheme includes granting restricted stock units (RSUs) to key executives, which could impact the company’s operational strategies and stakeholder interests by aligning management incentives with company performance.
The most recent analyst rating on (HK:2190) stock is a Buy with a HK$27.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.
More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H
Zylox-Tonbridge Medical Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the medical technology industry. The company focuses on developing and providing medical devices and technologies, with a significant presence in the Chinese market.
Average Trading Volume: 640,864
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.37B
For an in-depth examination of 2190 stock, go to TipRanks’ Overview page.